Trial Profile
A Retrospective, Multicenter Study Assessing the Effectiveness , Safety and Pharmacological Interactions of Ombitasvir/Paritaprevir/Ritonavir(OBV/PTV/r) ± Dasabuvir (DSV) ± Ribavirin (RBV) in Patients with Stage 4 or 5 Chronic Kidney Disease (CKD) and Hepatitis C Virus (HCV) Genotype 1 or 4 Infection in Real Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2018
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 28 Feb 2018 New trial record